Experimental CAR-T therapy takes on tough leukemia
Disease control
Not yet recruiting
This early-stage trial tests a new treatment called CT0991, which uses a patient's own immune cells engineered to attack leukemia cells. It will enroll 24 adults with acute myeloid leukemia that has returned or not responded to standard therapy. The main goals are to check safety…
Phase: PHASE1 • Sponsor: MEI HENG • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC